Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.

ABSTRACT:

Background

Treatment guidelines and U.S. Food and Drug Administration emergency use authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients with mild to moderate COVID-19 changed frequently as different SARS-CoV-2 variants emerged.

Objective

To evaluate whether early outpatient treatment with mAbs, overall and by mAb product, presumed SARS-CoV-2 variant, and immunocompromised status, is associated with reduced risk for hospitalization or death at 28 days.

Design

Hypothetical pragmatic randomized trial from observational data comparing mAb-treated patients with a propensity score-matched, nontreated control group.

Setting

Large U.S. health care system.

Participants

High-risk outpatients eligible for mAb treatment under

SUBMITTER: Kip KE 

PROVIDER: S-EPMC10074437 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature